Five-year NIH-funded program supports preclinical research, drug product manufacturing, regulatory preparation, and planned clinical studies, advancing MTTI’s EvaThera™ platform and oncology pipeline.

Read more MTTI Awarded $3.17 Million NCI Grant to Advance ¹⁷⁷Lu-EBRGD Development for Non-Small Cell Lung Cancer 

Industry Recognition Highlights EvaThera™ as a Next-Generation Pharmacokinetic Engineering Platform for Precision Radiopharmaceutical Therapy

Read more Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™

Largest Reported Clinical Dataset for an Albumin-Binding Radiotherapeutic Supports the Evans Blue Platform as a Foundational Technology for Next-Generation Targeted Radiopharmaceuticals

Read more Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT

FOR IMMEDIATE RELEASE WEST CHESTER, Pa.–(BUSINESS WIRE)–Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted…

Read more MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026

FOR IMMEDIATE RELEASE West Chester, PA (Business Wire) – May 28, 2026 – Molecular Targeting Technologies, Inc. (MTTI) announced the…

Read more Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026

FOR IMMEDIATE RELEASE WEST CHESTER, Pa. (BUSINESS WIRE) — Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of…

Read more MTTI Announces Dr. Danielle Meyrick to Lead Medical Team